Netarsudil改善原发性开角型青光眼或高眼压患者的房水流出易度:一项2期研究
这项双盲、随机、赋形剂对照的2期试验纳入20例POAG或OHT患者,单眼滴用0.02% Netarsudil、对侧眼用赋形剂,每日晨间一次共7天。第8天Netarsudil组日间平均流出易度较基线增加0.039 µL/min/mm Hg,赋形剂组增加0.007,治疗差异0.03(P≤.001);日间平均眼压变化分别为-4.52 mmHg和-0.98 mmHg,治疗差异-3.54 mmHg(P<.0001);巩膜表层静脉压变化分别为-0.79 mmHg和0.10 mmHg,治疗差异-0.89 mmHg(P<.001)。结论认为Netarsudil作用于传统流出通路近端和远端,通过改善小梁流出易度及降低EVP显著降低POAG和OHT患者眼压。
要点
- Netarsudil 0.02%每日一次可改善POAG/OHT患者日间平均流出易度
- 日间平均眼压降幅Netarsudil组-4.52 mmHg,赋形剂组-0.98 mmHg
- Netarsudil组巩膜表层静脉压下降0.79 mmHg,赋形剂组上升0.10 mmHg
核心结论
- Netarsudil通过改善小梁流出易度和降低巩膜表层静脉压,作用于传统流出通路近端和远端,显著降低POAG和OHT患者眼压。
研究设计与样本
- 双盲、随机、赋形剂对照的2期试验,20例POAG或OHT患者单眼滴用Netarsudil 0.02%、对侧眼用赋形剂,每日晨间一次共7天。
- 主要终点为第8天与第1天(基线)日间平均流出易度的变化,流出易度用Schiøtz眼压描记法测量,眼压用pneumotonometry测量,巩膜表层静脉压用自动静脉测压法测量。
主要发现
- 日间平均流出易度较基线增加:Netarsudil组0.039 µL/min/mm Hg,赋形剂组0.007 µL/min/mm Hg(Netarsudil组 vs 基线 P<.001),治疗差异0.03 µL/min/mm Hg(P≤.001)。
- 第8天日间平均眼压较基线变化:Netarsudil组-4.52 mm Hg,赋形剂组-0.98 mm Hg,治疗差异-3.54 mm Hg(P<.0001)。
- 日间平均巩膜表层静脉压较基线变化:Netarsudil组-0.79 mm Hg,赋形剂组0.10 mm Hg,治疗差异-0.89 mm Hg(P<.001)。
- 所有报告不良事件的患者均报告轻或中度结膜充血。
临床怎么用
- 对于POAG或OHT患者,Netarsudil 0.02%每日一次可作为通过改善小梁流出易度及降低EVP来降低眼压的用药选择。
- 用药期间应关注结膜充血这一不良事件。
局限性
- 原文未报告局限性内容。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Intraocular pressure (IOP) reduction is key to controlling primary open angle glaucoma (POAG). Pharmacotherapies for POAG or ocular hypertension (OHT) commonly lower IOP by increasing uveoscleral outflow or decreasing aqueous humor production. Netarsudil (Rhopressa), a Rho kinase inhibitor, reduces IOP by improving trabecular outflow facility, which is reduced in POAG. We investigated the effects of netarsudil on aqueous humor dynamics in patients with POAG or OHT. DESIGN: Double-masked, randomized, vehicle-controlled, Phase 2 trial. METHODS: Netarsudil 0.02% was instilled in 1 eye and vehicle into the contralateral eye of 20 patients once daily in the morning for 7 days. The primary endpoint was change in mean diurnal outflow facility on day 8 versus that on day 1 (baseline). Outflow facility was measured by using Schiøtz tonography, IOP by pneumotonometry, and episcleral venous pressure (EVP) by automated venomanometry. RESULTS: Eighteen patients (90%) completed the study. Mean diurnal outflow facility increased 0.039 versus 0.007 µL/min/mm Hg from baseline in the netarsudil- and the vehicle-treated groups, respectively (P < .001 vs. baseline for netarsudil), a treatment difference of 0.03 µL/min/mm Hg (P ≤ .001). Mean diurnal IOP change from baseline at day 8 was -4.52 mm Hg for netarsudil versus -0.98 mm Hg for vehicle, a treatment difference of -3.54 mm Hg (P < .0001). Mean diurnal EVP change from baseline was -0.79 mm Hg in the netarsudil-treated group versus 0.10 mm Hg for vehicle, a treatment difference of -0.89 mm Hg (P < .001). All patients reporting an adverse event reported conjunctival hyperemia of mild or moderate severity. CONCLUSIONS: Netarsudil acts on the conventional outflow pathway, both proximal and distal, to significantly reduce IOP in POAG and OHT by improving trabecular outflow facility and decreasing EVP.
引用
- Sit AJ, Gupta D, Kazemi A, et al. Netarsudil Improves Trabecular Outflow Facility in Patients with Primary Open Angle Glaucoma or Ocular Hypertension: A Phase 2 Study. Am J Ophthalmol. 2021. PMID: 33524367. doi:10.1016/j.ajo.2021.01.019
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。